<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9052">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05706298</url>
  </required_header>
  <id_info>
    <org_study_id>22LJMUSPONSOR010</org_study_id>
    <nct_id>NCT05706298</nct_id>
  </id_info>
  <brief_title>Active Breaks in People With Type 1 Diabetes</brief_title>
  <acronym>EXTOD-Active</acronym>
  <official_title>The Effect of Interrupting Sitting With Regular Active Breaks on Glycaemia and Daily Insulin Dose in Sedentary People With Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Liverpool John Moores University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Liverpool John Moores University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      the investigators aim to determine the effect of 4 weeks of frequent active breaks from&#xD;
      prolonged sitting on time in target glycaemic range in people with type 1 diabetes with high&#xD;
      habitual sedentary behaviour.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open-label randomised controlled trial, whereby participants will complete&#xD;
      pre-randomisation baseline procedures before allocation to 4wks of habitual activity&#xD;
      (control) or active breaks. Interstitial glucose concentrations (fGM), insulin dose and&#xD;
      physical activity/ postural transitions (ActivPAL) will be monitored throughout. To improve&#xD;
      generalisability and feasibility of recruiting the required number of participants, the study&#xD;
      will be completed in a free-living environment using remote data collection methods.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 7, 2022</start_date>
  <completion_date type="Anticipated">May 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomised controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in time in target glycaemic range</measure>
    <time_frame>change from baseline to final week of the intervention</time_frame>
    <description>flash glucose monitoring</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in glycaemic variability (coefficient of variation)</measure>
    <time_frame>change from baseline to final week of the intervention</time_frame>
    <description>flash glucose monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in insulin dose</measure>
    <time_frame>change from baseline to final week of the intervention</time_frame>
    <description>Insulin dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Concentration of Hba1c</measure>
    <time_frame>change from baseline to post intervention (4 weeks)</time_frame>
    <description>HbA1c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change Insulin to CHO ratio</measure>
    <time_frame>change from baseline to post intervention (4 weeks)</time_frame>
    <description>Insulin to CHO ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Anxiety and depression</measure>
    <time_frame>change from baseline to post intervention (4 weeks)</time_frame>
    <description>The Hospital Anxiety and Depression Scale (HADS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Diabetes Quality of Life</measure>
    <time_frame>change from baseline to post intervention (4 weeks)</time_frame>
    <description>Diabetes Quality of Life (DQOL) questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Health-related quality of life</measure>
    <time_frame>change from baseline to post intervention (4 weeks)</time_frame>
    <description>Short Form-12 Health Survey (SF-12)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Height</measure>
    <time_frame>change from baseline to post intervention (4 weeks)</time_frame>
    <description>Height (cm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in weight</measure>
    <time_frame>change from baseline to post intervention (4 weeks)</time_frame>
    <description>weight (kg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in BMI</measure>
    <time_frame>change from baseline to post intervention (4 weeks)</time_frame>
    <description>BMI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in waist circumference</measure>
    <time_frame>change from baseline to post intervention (4 weeks)</time_frame>
    <description>waist circumference (cm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in triglycerides.</measure>
    <time_frame>change from baseline to post intervention (4 weeks)</time_frame>
    <description>triglycerides.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Insulin Sensitivity Score</measure>
    <time_frame>change from baseline to post intervention (4 weeks)</time_frame>
    <description>LogeIS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>c-peptide</measure>
    <time_frame>baseline</time_frame>
    <description>c-peptide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in sedentary behaviour</measure>
    <time_frame>change from baseline to final week of the intervention</time_frame>
    <description>minutes of sitting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in carbohydrate intake</measure>
    <time_frame>change from baseline to final week of the intervention</time_frame>
    <description>carbohydrate intake</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">118</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Habitual lifestyle</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants in the control group will be asked to maintain their habitual lifestyle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active breaks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be asked to interrupt sitting with 3 min bouts of walking every 30 min (16 bouts per day, equalling 48 min of walking) from 9am-5pm every day throughout the 4 week period. To improve adherence should participants miss a bout of walking they will be asked to do 6 min during the next bout.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Active Breaks</intervention_name>
    <description>Participants will be asked to interrupt sitting with 3 min bouts of walking every 30 min from 9am-5pm</description>
    <arm_group_label>Active breaks</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  T1D diagnosis more than 3 years ago&#xD;
&#xD;
          -  Sedentary (&gt; 10h per waking day sedentary (sitting or lying)&#xD;
&#xD;
          -  Using insulin therapy with multiple daily injections or insulin pump&#xD;
&#xD;
          -  Aged 18-66 (UK retirement age)&#xD;
&#xD;
          -  Use of Abbot FreeStyle Libre 2 fGM (&gt;6 weeks to avoid potential lifestyle changes as a&#xD;
             result of sensor use)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Engaged in structured planned exercise (e.g. running, cycling, gym, or sports)&#xD;
&#xD;
          -  Pregnancy or planning to become pregnant&#xD;
&#xD;
          -  &lt;6 months postpartum or stopped breastfeeding &lt;1 month before recruitment&#xD;
&#xD;
          -  Existing cerebrovascular or cardiovascular disease&#xD;
&#xD;
          -  Significant history of hyperglycaemia (HbA1c &gt;85 mmol/mol)&#xD;
&#xD;
          -  History of severe hypoglycaemia requiring third party assistance within the last 3&#xD;
             months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>66 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Liverpool John Moores University</name>
      <address>
        <city>Liverpool</city>
        <zip>L33AF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Cocks, PhD</last_name>
      <phone>07540191292</phone>
      <email>m.s.cocks@ljmu.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>December 21, 2022</study_first_submitted>
  <study_first_submitted_qc>January 20, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 31, 2023</study_first_posted>
  <last_update_submitted>January 20, 2023</last_update_submitted>
  <last_update_submitted_qc>January 20, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

